ArticleImmunology and cell biology2016
Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells.
Article in Immunology and cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications.Molecular biomedicine · 2025Review
- Glycolysis-related five-gene signature correlates with prognosis and immune infiltration in gastric cancer.World journal of gastrointestinal oncology · 2024Article
- Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Cutaneous Malignant Melanoma Presenting as an Isolated Splenic Metastasis: An Update.World journal of oncology · 2023Review
- IDO1 Promotes the Progression of NSCLC by Regulating the Polarization of M2 Macrophages.International journal of general medicine · 2023Article
- Review
- Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.Cancers · 2021Review
- Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals.Biomedicines · 2021Article
- Role of the CBX Molecular Family in Lung Adenocarcinoma Tumorigenesis and Immune Infiltration.Frontiers in genetics · 2021Article
- Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.Advances in experimental medicine and biology · 2021Article
- Anti-Tumoral and Anti-Angiogenic Effects of Low-DilutedFrontiers in oncology · 2021Article
- The function and clinical application of extracellular vesicles in innate immune regulation.Cellular & molecular immunology · 2020Review
- RNA-seq Analysis of Wild-Type vs. FOXC2-Deficient Melanoma Cells Reveals a Role for the FOXC2 Transcription Factor in the Regulation of Multiple Oncogenic Pathways.Frontiers in oncology · 2020Article
- Simulated microgravity-mediated reversion of murine lymphoma immune evasion.Scientific reports · 2019Article
- Review
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.Frontiers in immunology · 2019Review
- The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity.Trends in cancer · 2018Review
- Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.Cancer immunology, immunotherapy : CII · 2018Article
- Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are key regulators of host immunity that are capable of inducing either immune tolerance or activation. In addition to their well-characterized role in shaping immune responses to foreign pathogens, DCs are also known to be critical for the induction and maintenance of anti-tumor immune responses. Therefore, it is important to understand how tumors influence the function of DCs and the quality of immune responses they elicit. Although the majority of studies in this field to date have utilized either immortalized DC lines or DC populations that have been generated under artificial conditions from hematopoietic precursors in vitro, we wished to investigate how tumors impact the function of already differentiated, tissue-resident DCs. Therefore, we used both an ex vivo and in vivo model system to assess the influence of melanoma-derived factors on DC maturation and activation. In ex vivo studies with freshly isolated splenic DCs, we demonstrate that the extent to which DC maturation and activation are altered by these factors correlates with melanoma tumorigenicity, and we identify partial roles for tumor-derived transforming growth factor (TGF)β1 and vascular endothelial growth factor (VEGF)-A in the altered functionality of DCs. In vivo studies using a lung metastasis model of melanoma also demonstrate tumorigenicity-dependent alterations to the function of lung-resident DCs, and skewed production of proinflammatory cytokines and chemokines by these tumor-altered cells is associated with recruitment of an immune infiltrate that may ultimately favor tumor immune escape and outgrowth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.